The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

T Zuberbier, W Aberer, R Asero, A H Abdul Latiff, D Baker, B Ballmer-Weber, J A Bernstein, C Bindslev-Jensen, Z Brzoza, R Buense Bedrikow, G W Canonica, M K Church, T Craig, I V Danilycheva, C Dressler, L F Ensina, A Giménez-Arnau, K Godse, M Gonçalo, C GrattanJ Hebert, M Hide, A Kaplan, A Kapp, C H Katelaris, E Kocatürk, K Kulthanan, D Larenas-Linnemann, T A Leslie, M Magerl, P Mathelier-Fusade, R Y Meshkova, M Metz, A Nast, E Nettis, H Oude-Elberink, S Rosumeck, S S Saini, M Sánchez-Borges, P Schmid-Grendelmeier, P Staubach, G Sussman, E Toubi, G A Vena, C Vestergaard, B Wedi, R N Werner, Z Zhao, M Maurer

Research output: Contribution to journalJournal articleCommunication

99 Downloads (Pure)

Abstract

This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

Original languageEnglish
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number7
Pages (from-to)1393-1414
ISSN0105-4538
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Urticaria
Dermatology
Allergy and Immunology
Hypersensitivity
Organizations
Guidelines
Mastocytosis
European Union
Quality of Life

Keywords

  • angioedema
  • consensus
  • evidence-based
  • hives
  • wheal

Cite this

Zuberbier, T ; Aberer, W ; Asero, R ; Abdul Latiff, A H ; Baker, D ; Ballmer-Weber, B ; Bernstein, J A ; Bindslev-Jensen, C ; Brzoza, Z ; Buense Bedrikow, R ; Canonica, G W ; Church, M K ; Craig, T ; Danilycheva, I V ; Dressler, C ; Ensina, L F ; Giménez-Arnau, A ; Godse, K ; Gonçalo, M ; Grattan, C ; Hebert, J ; Hide, M ; Kaplan, A ; Kapp, A ; Katelaris, C H ; Kocatürk, E ; Kulthanan, K ; Larenas-Linnemann, D ; Leslie, T A ; Magerl, M ; Mathelier-Fusade, P ; Meshkova, R Y ; Metz, M ; Nast, A ; Nettis, E ; Oude-Elberink, H ; Rosumeck, S ; Saini, S S ; Sánchez-Borges, M ; Schmid-Grendelmeier, P ; Staubach, P ; Sussman, G ; Toubi, E ; Vena, G A ; Vestergaard, C ; Wedi, B ; Werner, R N ; Zhao, Z ; Maurer, M. / The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 7. pp. 1393-1414.
@article{c2ecf3cab00b42558f86f1e48bf2633d,
title = "The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria",
abstract = "This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20{\%}. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.",
keywords = "angioedema, consensus, evidence-based, hives, wheal",
author = "T Zuberbier and W Aberer and R Asero and {Abdul Latiff}, {A H} and D Baker and B Ballmer-Weber and Bernstein, {J A} and C Bindslev-Jensen and Z Brzoza and {Buense Bedrikow}, R and Canonica, {G W} and Church, {M K} and T Craig and Danilycheva, {I V} and C Dressler and Ensina, {L F} and A Gim{\'e}nez-Arnau and K Godse and M Gon{\cc}alo and C Grattan and J Hebert and M Hide and A Kaplan and A Kapp and Katelaris, {C H} and E Kocat{\"u}rk and K Kulthanan and D Larenas-Linnemann and Leslie, {T A} and M Magerl and P Mathelier-Fusade and Meshkova, {R Y} and M Metz and A Nast and E Nettis and H Oude-Elberink and S Rosumeck and Saini, {S S} and M S{\'a}nchez-Borges and P Schmid-Grendelmeier and P Staubach and G Sussman and E Toubi and Vena, {G A} and C Vestergaard and B Wedi and Werner, {R N} and Z Zhao and M Maurer",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "7",
doi = "10.1111/all.13397",
language = "English",
volume = "73",
pages = "1393--1414",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Online",
number = "7",

}

Zuberbier, T, Aberer, W, Asero, R, Abdul Latiff, AH, Baker, D, Ballmer-Weber, B, Bernstein, JA, Bindslev-Jensen, C, Brzoza, Z, Buense Bedrikow, R, Canonica, GW, Church, MK, Craig, T, Danilycheva, IV, Dressler, C, Ensina, LF, Giménez-Arnau, A, Godse, K, Gonçalo, M, Grattan, C, Hebert, J, Hide, M, Kaplan, A, Kapp, A, Katelaris, CH, Kocatürk, E, Kulthanan, K, Larenas-Linnemann, D, Leslie, TA, Magerl, M, Mathelier-Fusade, P, Meshkova, RY, Metz, M, Nast, A, Nettis, E, Oude-Elberink, H, Rosumeck, S, Saini, SS, Sánchez-Borges, M, Schmid-Grendelmeier, P, Staubach, P, Sussman, G, Toubi, E, Vena, GA, Vestergaard, C, Wedi, B, Werner, RN, Zhao, Z & Maurer, M 2018, 'The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 7, pp. 1393-1414. https://doi.org/10.1111/all.13397

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. / Zuberbier, T; Aberer, W; Asero, R; Abdul Latiff, A H; Baker, D; Ballmer-Weber, B; Bernstein, J A; Bindslev-Jensen, C; Brzoza, Z; Buense Bedrikow, R; Canonica, G W; Church, M K; Craig, T; Danilycheva, I V; Dressler, C; Ensina, L F; Giménez-Arnau, A; Godse, K; Gonçalo, M; Grattan, C; Hebert, J; Hide, M; Kaplan, A; Kapp, A; Katelaris, C H; Kocatürk, E; Kulthanan, K; Larenas-Linnemann, D; Leslie, T A; Magerl, M; Mathelier-Fusade, P; Meshkova, R Y; Metz, M; Nast, A; Nettis, E; Oude-Elberink, H; Rosumeck, S; Saini, S S; Sánchez-Borges, M; Schmid-Grendelmeier, P; Staubach, P; Sussman, G; Toubi, E; Vena, G A; Vestergaard, C; Wedi, B; Werner, R N; Zhao, Z; Maurer, M.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 7, 07.2018, p. 1393-1414.

Research output: Contribution to journalJournal articleCommunication

TY - JOUR

T1 - The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

AU - Zuberbier, T

AU - Aberer, W

AU - Asero, R

AU - Abdul Latiff, A H

AU - Baker, D

AU - Ballmer-Weber, B

AU - Bernstein, J A

AU - Bindslev-Jensen, C

AU - Brzoza, Z

AU - Buense Bedrikow, R

AU - Canonica, G W

AU - Church, M K

AU - Craig, T

AU - Danilycheva, I V

AU - Dressler, C

AU - Ensina, L F

AU - Giménez-Arnau, A

AU - Godse, K

AU - Gonçalo, M

AU - Grattan, C

AU - Hebert, J

AU - Hide, M

AU - Kaplan, A

AU - Kapp, A

AU - Katelaris, C H

AU - Kocatürk, E

AU - Kulthanan, K

AU - Larenas-Linnemann, D

AU - Leslie, T A

AU - Magerl, M

AU - Mathelier-Fusade, P

AU - Meshkova, R Y

AU - Metz, M

AU - Nast, A

AU - Nettis, E

AU - Oude-Elberink, H

AU - Rosumeck, S

AU - Saini, S S

AU - Sánchez-Borges, M

AU - Schmid-Grendelmeier, P

AU - Staubach, P

AU - Sussman, G

AU - Toubi, E

AU - Vena, G A

AU - Vestergaard, C

AU - Wedi, B

AU - Werner, R N

AU - Zhao, Z

AU - Maurer, M

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/7

Y1 - 2018/7

N2 - This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

AB - This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

KW - angioedema

KW - consensus

KW - evidence-based

KW - hives

KW - wheal

U2 - 10.1111/all.13397

DO - 10.1111/all.13397

M3 - Journal article

C2 - 29336054

VL - 73

SP - 1393

EP - 1414

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 7

ER -